Neumora Therapeutics, Inc. (NASDAQ:NMRA – Get Free Report) Director Matthew K. Fust sold 14,049 shares of the firm’s stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $17.03, for a total transaction of $239,254.47. Following the sale, the director now owns 20,100 shares in the company, valued at approximately $342,303. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Neumora Therapeutics Trading Down 2.8 %
NMRA stock opened at $16.49 on Friday. The stock has a 50-day moving average price of $12.73 and a two-hundred day moving average price of $11.36. The company has a market cap of $2.63 billion and a PE ratio of -6.44. Neumora Therapeutics, Inc. has a 12-month low of $8.33 and a 12-month high of $21.00.
Neumora Therapeutics (NASDAQ:NMRA – Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.37) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.37). Equities analysts forecast that Neumora Therapeutics, Inc. will post -1.48 EPS for the current fiscal year.
Institutional Trading of Neumora Therapeutics
Analyst Ratings Changes
Several research firms have recently issued reports on NMRA. Royal Bank of Canada restated an “outperform” rating and set a $29.00 price objective on shares of Neumora Therapeutics in a report on Wednesday, September 4th. Mizuho assumed coverage on Neumora Therapeutics in a research note on Monday, July 8th. They issued an “outperform” rating and a $20.00 price target on the stock. HC Wainwright began coverage on shares of Neumora Therapeutics in a research note on Tuesday, October 1st. They set a “buy” rating and a $30.00 price objective for the company. Finally, Needham & Company LLC reiterated a “buy” rating and set a $23.00 price objective on shares of Neumora Therapeutics in a report on Friday. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $22.83.
View Our Latest Stock Report on Neumora Therapeutics
About Neumora Therapeutics
Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
Further Reading
- Five stocks we like better than Neumora Therapeutics
- Conference Calls and Individual Investors
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- Manufacturing Stocks Investing
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- MarketBeat Week in Review – 10/14 – 10/18
Receive News & Ratings for Neumora Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neumora Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.